Prognostic significance of serum prolactin levels in advanced breast cancer

Other OA: bronze CC0
⚙ AI-generated summary by qwen3.7-flash, 2026-10-11 ⓘ

In 135 postmenopausal patients with advanced breast cancer, serum prolactin levels greater than or equal to 500 mIUl-1 were associated with poor response to endocrine therapy and significantly shorter survival.

One-sentence paraphrase of the abstract; not a substitute for reading it. No clinical advice. How this works

Abstract

Serum prolactin concentrations were measured in 135 postmenopausal patients with advanced breast cancer prior to their treatment with one of 3 endocrine therapies: aminoglutethimide (AG), tamoxifen (T) + AG, or T + AG + danazol. The mean level of prolactin was higher, and there were more individuals with levels of prolactin greater than or equal to 500 mIUl-1, in the group of patients who did not respond to treatment. Of the patients whose disease progressed, those with prolactin levels greater than or equal to 500 mIUl-1 had a significantly shorter survival. It appears that high prolactin levels indicate a poor prognosis to endocrine therapy and the probability of a shorter than average survival time.

My notes (saved in your browser only)

MeSH descriptors

Breast Neoplasms Prolactin Aminoglutethimide Aminoglutethimide Breast Neoplasms Breast Neoplasms Breast Neoplasms Danazol Danazol Drug Therapy, Combination Female Humans Menopause Prognosis Prolactin Tamoxifen Tamoxifen

Citation neighborhood (no data yet)

We don't have any in-corpus citations linked to this paper yet. The paper's references may be in our DB but unresolved to ``paper_id`` (resolution happens at ingest when the cited DOI matches a row we already have). Run the cross-source citation reconcile pass to retry.

References (22)

Source provenance

openalex
last seen: 2026-05-10T10:45:29.646959+00:00
pubmed
last seen: 2026-10-08T21:58:26.348914+00:00
License: CC0 · commercial use OK